Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Processa Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Processa Pharmaceuticals's regulatory disclosures and financial reporting.
Processa Pharmaceuticals, Inc. is registering 10,000,000 additional shares of its common stock, par value $0.0001 per share, for issuance under its Amended and Restated 2019 Omnibus Incentive Plan. These shares support equity-based compensation awards such as stock options and other incentives granted to eligible participants in the plan.
The amendment to the plan to add the 10,000,000 shares was approved by stockholders at a special meeting held on September 11, 2025. This filing updates the existing Form S-8 registrations and incorporates the company’s recent reports and governing documents by reference.
Wendy Guy, identified as the reporting person and listed as Chief Administrative Officer, submitted an amended Form 4 for Processa Pharmaceuticals, Inc. (PCSA). The filing states a transaction date of 07/24/2025 and records a disposition of 26,339 shares of the issuer's common stock (transaction code V). After the reported transaction the filing shows beneficial ownership of 8,335 shares held indirectly through CorLyst, LLC.
The amendment expressly notes it was filed to retract a prior Form 4 that was filed in error. The amended Form 4 is signed via power of attorney on behalf of Wendy Guy by John J. Wolfel and dated 09/18/2025.
Processa Pharmaceuticals (PCSA) insider amendment: This amended Form 4, filed by Director Justin W. Yorke, corrects a prior filing submitted in error and reports changes in his holdings. The filing shows a disposition of 3,737 shares of common stock on 07/24/2025. After the reported transactions, Yorke beneficially owns 12,400 shares indirectly via a Directed Trust Company account for his IRA and 31,232 shares indirectly via Richland Fund, LLC. The amendment also reports warrants exercisable for common stock at a $0.65 price (expiring 01/29/2030) associated with the Directed Trust Company IRA: 12,400 and 6,200 underlying shares respectively. The form is signed by attorney-in-fact John J. Wolfel on behalf of Yorke.
Processa Pharmaceuticals, Inc. (PCSA) filed an amended Form 4 to correct an earlier filing. The amendment states the prior Form 4 was filed in error and retracts that prior report. The filing lists David Young (President, Research & Development and director) as the reporting person and shows a transaction date of 07/24/2025. The Table I entries indicate a disposition of 217,332 common shares and beneficial ownership reported as 30,985 shares direct plus indirect holdings: 10,786 shares via the Young-Plaisance Revocable Trust, 18,544 shares via CorLyst, LLC. The amendment is signed by David Young via attorney-in-fact John J. Wolfel on 09/18/2025.
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), amended a prior filing to report ownership of 28,000 restricted stock units. The RSUs convert to common stock and are structured to vest 50% on July 16, 2025, with the remaining 50% contingent on achievement of specified performance criteria. The amendment retracts an earlier Form 4 that was filed in error. The reported transaction date is July 24, 2025, and the amended Form 4 was signed by attorney-in-fact on September 18, 2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.
Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.
Processa Pharmaceuticals, Inc. (PCSA) amended a prior Form 4 to correct reported insider holdings for reporting person Neal James R, who is identified as a director. The filing shows restricted stock granted with $0 price that vested subject to the earlier of June 28, 2025 or the next annual meeting, and records an acquisition of 31,206 restricted shares. The filing reports 36,275 common shares beneficially owned following the reported transactions. The amendment states it was filed to retract a prior Form 4 that was filed in error and to correct the beneficially owned shares previously reported on a Form 4 filed September 18, 2024. The form was signed by an attorney-in-fact on behalf of the reporting person.
Processa Pharmaceuticals insider amendment reports a corrected sale and existing family trust holdings. The filing amends a prior Form 4 to retract an earlier filing error and discloses a disposition of 38,727 shares of common stock reported as a sale. Following the reported transaction the reporting person is shown as beneficially owning 43,500 shares indirectly through the Lin Family Trust. The reporting person is an officer (Chief Business - Strategy Officer) and a director of the company. The amendment clarifies prior reporting and does not include derivative transactions or exercise details.
Form 4/A filed for Processa Pharmaceuticals, Inc. (PCSA) amends earlier reporting. The reporting person is Sian Bigora, identified as Chief Development Officer and Director. The earliest transaction date reported is 07/24/2025, with an amendment date of 07/28/2025 and a signature entry dated 09/18/2025. The filing shows a disposition of 33,626 shares of common stock and continued beneficial ownership of 6,668 shares held indirectly through CorLyst, LLC. The amendment states it was filed to retract a prior Form 4 that was filed in error. The document discloses insider role, the specific share disposition, and the indirect ownership vehicle.